CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 4, 2015
Result type: Reports
Project Number: SR0422-000
Product Line: Reimbursement Review

Generic Name: Umeclidinium

Brand Name: Incruse Ellipta

Manufacturer: GlaxoSmithKline Inc.

Therapeutic Area: Chronic obstructive pulmonary disease

Indications: Chronic Obstructive Pulmonary Disease (COPD)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: September 18, 2015

Recommendation Type: List with criteria/condition